首頁 > 市場調查報告書 > 製藥

眼科藥物

市場調查報告書

商品編碼

1548860

眼科藥品市場規模、佔有率和成長分析：按產品、劑型、藥物類別和地區 - 產業預測，2024-2031 年

Ophthalmic Drugs Market Size, Share, Growth Analysis, By Product (Prescription Drugs, OTC Drug), By Dosage Form (Eye Drops, Eye Solutions & Suspensions), By Drug class (Anti-allergy, Anti-inflammatory), By Region - Industry Forecast 2024-2031

出版日期: 2024年08月31日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球眼科藥物市場規模為309億美元，從2023年的333.1億美元成長到2031年的607億美元，預計在預測期內（2024-2031年）複合年成長率為7.8%。

眼科藥品市場的成長是由研發力度加大、主要產業參與者的策略性舉措以及眼科領域未滿足的醫療需求所推動的。據估計，有 22 億人患有視力障礙，其中約 10 億人可以透過適當的治療來預防，因此市場擴張存在重大機會。與老齡化相關的疾病是失明和視力喪失的主要原因，不僅影響個人，也給政府帶來沉重的財政負擔。例如，僅與近視相關的視力喪失就造成約 2,440 億美元的損失。此類與眼睛相關的問題的高盛行率預計將推動對眼科藥物的需求。 COVID-19大流行對眼科藥品市場產生了負面影響，導致視野檢查（93.84%）、諮詢（92.52%）、藥物（19.63%）和手術（72.74%）大幅下降。這種下降反映了青光眼和其他眼科疾病治療的下降。然而，由於廣泛接種 COVID-19 疫苗和病例減少，預計市場將會復甦。領先公司增加研發投資可能會推動未來幾年的成長。例如，愛爾康將研發支出從2020年的6.73億美元增加到2021年的8.42億美元，聚焦在隱形眼鏡、白內障治療和青光眼解決方案等產品。此外，Nicox 的 NCX 470 等強大的產品線計劃於 2029 年推出，以及諾華製藥和 Amring Pharmaceuticals 等公司的策略性舉措將進一步推動市場成長。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Novartis AG（Switzerland）
Roche Holding AG（Switzerland）
Pfizer Inc.（US）
Santen Pharmaceutical Co., Ltd.（Japan）
Bayer AG（Germany）
Johnson & Johnson（US）
Merck & Co., Inc.（US）
Bausch Health Companies Inc.（Canada）
Alcon, Inc.（Switzerland）
GlaxoSmithKline plc（UK）
Eli Lilly and Company（US）
Regeneron Pharmaceuticals, Inc.（US）
Otsuka Pharmaceutical Co., Ltd.（Japan）
Aerie Pharmaceuticals, Inc.（US）
Carl Zeiss Meditec AG（Germany）
Topcon Corporation（Japan）
Senju Pharmaceutical Co., Ltd.（Japan）
AbbVie Inc.（US）
UCB SA（Belgium）
Hikma Pharmaceuticals PLC（UK）
Lupin Pharmaceuticals, Inc.（India）
Tarsus Pharmaceuticals, Inc.（US）

簡介目錄

Product Code: SQMIG35I2222

Global Ophthalmic Drugs Market size was valued at USD 30.90 Billion in 2022 and is poised to grow from USD 33.31 Billion in 2023 to USD 60.75 Billion by 2031, at a CAGR of 7.8% during the forecast period (2024- 2031).

The ophthalmic drugs market is poised for growth driven by increased research and development efforts, strategic initiatives from major industry players, and unmet medical needs within the field of ophthalmology. With an estimated 2.2 billion people experiencing vision impairment, including around 1 billion cases that could be prevented with proper treatment, there is a significant opportunity for market expansion. Age-related conditions are a primary cause of blindness and vision loss, which not only affects individuals but also imposes a substantial financial burden on governments. For instance, myopia-related vision impairment alone costs approximately USD 244 billion. This high prevalence of eye-related issues is expected to drive demand for ophthalmic drugs. The COVID-19 pandemic adversely impacted the ophthalmic drugs market, leading to substantial reductions in visual field checkups (93.84%), clinical visits (92.52%), medication releases (19.63%), and surgical procedures (72.74%). This decline indicates a reduction in the treatment of glaucoma and other eye disorders. However, with the advent of widespread COVID-19 vaccination and a decrease in cases, the market is anticipated to recover. Increased R&D investments by major companies are likely to fuel growth in the coming years. For instance, Alcon raised its R&D expenditure from USD 673 million in 2020 to USD 842 million in 2021, focusing on products like contact lenses, cataract treatments, and glaucoma solutions. Additionally, a strong pipeline of promising drugs, such as Nicox's NCX 470, expected to launch by 2029, and strategic moves by companies like Novartis Pharmaceuticals and Amring Pharmaceuticals, are likely to further drive market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ophthalmic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Ophthalmic Drugs Market Segmental Analysis

The global ophthalmic drugs market is segmented based on drug class, drug disease, drug dosage, drug route of administration, dosage type, product type and region. Based on product, the market is segmented into prescription durgs, OTC drugs. Based on drug class, the market is segmented into Anti-allergy, Anti-inflammatory (Non-steroidal drugs, Steroidal drugs), Anti-VEGF Agents, Anti-glaucoma, Gene and Cell Therapy, Others. Based on drug disease, dry eye, allergies, glaucoma, infection, retinal disorders, uveitis, others. Based on dosage form market is segmented into, gels, eye solutions and suspensions, capsules and tablets, eye drops, ointments, others. Based on drug route of administration market is segmented into, topical local ocular systemic. Based on type, the market is segmented into branded drugs, generic drugs. Based on Region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Ophthalmic Drugs Market

The growing prevalence of eye conditions such as cataracts, glaucoma, and macular degeneration is a major factor propelling the ophthalmic drugs market. Contributing to this rise are the aging population, shifts in lifestyle, and the increasing occurrence of chronic health issues, all of which amplify the need for effective ophthalmic treatments. As these eye diseases become more common, the demand for ophthalmic drugs is expected to increase correspondingly. The aging demographic, combined with modern lifestyle changes and the prevalence of chronic conditions, highlights the need for enhanced medical solutions to address these vision-related challenges.

Restraints in the Global Ophthalmic Drugs Market

The steep costs associated with ophthalmic drugs and treatments can act as a significant barrier, especially in developing regions where healthcare budgets are constrained and affordability is a major issue. The expenses involved in drug development, production, and distribution contribute to the overall high price of treatments, limiting access for certain patient groups. These financial challenges can impede the availability of essential ophthalmic care in less affluent areas, where limited resources and lower healthcare funding make it difficult for patients to afford necessary treatments. As a result, the high costs of ophthalmic therapies continue to be a critical factor affecting their accessibility and uptake in economically disadvantaged regions.

Market Trends of the Global Ophthalmic Drugs Market

The ophthalmic drugs market is increasingly moving toward personalized medicine, emphasizing treatments that are customized based on individual patient characteristics. This shift is driven by advancements in genomic research and precision medicine, which facilitate the creation of targeted therapies that enhance treatment efficacy and patient satisfaction. These developments allow for more precise and individualized approaches to eye care, improving therapeutic outcomes by tailoring treatments to each patient's unique genetic and clinical profile. This trend towards personalized ophthalmic therapies reflects a broader movement within the medical field to offer more effective and patient-centric treatment options.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors of The Market
Degree Of Competition
Top Investment Pockets
Market Attractive Index
Ecosystem Mapping
Technology Analysis
Cost Analysis
Market Trend Analysis
Competition Analysis
Supply chain analysis
Investment Analysis
Application-Specific Analysis
Patent analysis
Trade analysis
Case study analysis

Ophthalmic Drugs Market by Products

Market Overview
Prescription Drugs
OTC Drug

Ophthalmic Drugs Market by Drug Class

Market overview
Anti-allergy, Anti-inflammatory
- Non-steroidal drugs
- Steroidal drugs
Anti-VEGF Agents
Anti-glaucoma
Gene and Cell Therapy
Others

Ophthalmic Drugs Market by Disease

Market overview
Dry Eye
- Gels
- Eye Solutions & Suspensions
- Capsules & Tablets
- Eye Drops
- Ointments
Allergies
- Gels
- Eye Solutions & Suspensions
- Capsules & Tablets
- Eye Drops
- Ointments
Glaucoma
- Gels
- Eye Solutions & Suspensions
- Capsules & Tablets
- Eye Drops
- Ointments
Infection
- Gels
- Eye Solutions & Suspensions
- Capsules & Tablets
- Eye Drops
- Ointments
Retinal disorders
- Type
- Macular Degeneration
- Diabetic Retinopathy
- Dosage Type
- Gels
- Eye Solutions & Suspensions
- Capsules & Tablets
- Eye Drops
- Ointments
Uveitis
- Gels
- Eye Solutions & Suspensions
- Capsules & Tablets
- Eye Drops
- Ointments
Others

Ophthalmic Drugs Market by Route of Administration

Market overview
Topical
Local Ocular
- Retinal Disorders
- Subconjunctival
- Intravitreal
- Retrobulbar
- Intracameral
Systemic

Ophthalmic Drugs Market by Dosage Form

Market Overview
Gels
Eye Solutions & Suspensions
Capsules and Tablets
Eye Drops
Ointments

Ophthalmic Drugs Market by Type

Market Overview
Branded Drugs
Generic Drugs

Ophthalmic Drugs Market by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Santen Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alcon, Inc. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aerie Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Carl Zeiss Meditec AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Topcon Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Senju Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S.A. (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Pharmaceuticals, Inc. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tarsus Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments